FSD Pharma Advances Clinical Development of Lucid-21-302 with New Ethics Submission in Australia

FSD Pharma Inc., a Toronto-based biopharmaceutical company, has announced the submission of a Phase-1 Multiple Ascending Doses (MAD) clinical trial application for its drug Lucid-21-302, to an ethics committee in Australia. This submission follows the successful completion of a Phase-1 Single Ascending Dose (SAD) study of the same compound.

Lucid-21-302 is being developed as a novel neuroprotective treatment for Multiple Sclerosis (MS). It has demonstrated in preclinical models the ability to prevent demyelination, which is a major cause of MS. The drug, which does not modulate the immune system, was found to be safe and well-tolerated in its initial human trials, with no significant pharmacokinetic differences observed between fed and fasted states.

Dr. Andrzej Chruscinski, VP of Scientific and Clinical Affairs at FSD Pharma, expressed optimism about the new trial, highlighting its importance in the drug's continuing development and the upcoming phase-2 clinical trials.